Nathan Connell on Real-World Evidence: A Safe Switch to New rFVIIa Avoided Over $550K in Costs
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn:
“New Research: Real-World Evidence on Recombinant Factor VIIa Substitution
I’m excited to share our team’s latest publication in Clinical and Applied Thrombosis/Hemostasis. We conducted a retrospective evaluation of our conversion from eptacog alfa (NovoSeven) to eptacog beta (Sevenfact) to assess both clinical safety and financial impact at Brigham and Women’s Hospital.
Key Findings:
- Safety: The transition to eptacog beta showed no adverse thrombotic events across the patient cohort.
- Efficacy: Effective management was maintained for indications including hemophilia bleeding and peri-procedural management.
- Impact: The medication use evaluation identified an estimated cost avoidance of $554,400 over 12 months.
This study supports the viability of therapeutic interchange for rFVIIa products, offering a pathway for other institutions to maintain high-quality care while optimizing costs.
Read the full open-access article here.”
Title: Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center
Authors: Alyssa R. George, Katelyn W. Sylvester, Dareen M. Kanaan, Prabashni Reddy, John R. Fanikos, Jean M. Connors, Nathan T. Connell
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Feb 17, 2026, 16:34ISTH Names Five Global Recipients of 2026 Esteemed Career Awards
-
Feb 17, 2026, 16:16Flora Peyvandi: A Multicenter Initiative to Improve Guideline Adherence in Pediatric ITP
-
Feb 17, 2026, 16:14Hendrianus The: Intravenous Cangrelor in Hemodynamically Unstable Patients Undergoing PCI
-
Feb 17, 2026, 15:42Paul Wischmeyer: Nutrient Absorption in the GI Tract
-
Feb 17, 2026, 15:40Mahesan Subramaniam: Reversing Age-Related Decline in Blood Stem Cells
-
Feb 17, 2026, 15:38Wolfgang Miesbach: How a Single Mutation Can Flip Immunity into VITT
-
Feb 17, 2026, 15:34Jeff June: When Safety Warnings Outlive the Evidence – What Statins Teach Us About Stroke Prevention and Biology
-
Feb 17, 2026, 15:32Gabrielle Sarlon: Key Messages to Improve VTE Management in Women of Childbearing Age
-
Feb 17, 2026, 15:27Piezo1 Gain-of-Function Mutation Explains Thromboembolic Complications in Hereditary Xerocytosis – JTH